Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases (vol 17, pg 130, 2019)

In a post-hoc analysis of data from phase 3 clinical trials, vedolizumab significantly improved patient-reported symptoms of UC and CD as early as week 2 of treatment, continuing through the first 6 weeks-especially when given as first-line biologic therapy.